Gain Early Access to the Neurotech Frontier
Kaleida Capital is a next-generation venture platform focused exclusively on neurotechnology, computational biology, and deeptech AI. We are led by scientists with a proven ability to spot winners early—before they hit the mainstream radar.
With a track record that includes multiple Nobel-affiliated investments, 6.5x realized MOIC at a prior fund, and early participation in generational companies like Anthropic and Manifest (J&J exit), Kaleida offers institutional-grade access to category-defining innovation.
Our Edge:
Deep scientific fluency—Stanford-trained PhD team with 10+ years in neural interfaces, diagnostics, and platform bioengineering
Proprietary sourcing—via academia, scientific networks, and targeted founder relationships
Investment rigor—valuation discipline, IP defensibility, and regulatory-aware screening
Early positioning in AI x biology companies with asymmetric upside
How We Work with Investors:
We operate through SPVs and private syndicates—not a public fund. Our model is designed for long-term partners who seek exposure to the neurotech frontier without the overhead of traditional venture structures.
We share deal flow selectively and only when conviction is high.